Publications
171
Citations
2,906
Est. group size
~14
Recurring co-author estimate
Active years
34
Publishing since 1993
Lufang Zhou's research focuses on mitochondrial biology and its role in disease, spanning cancer treatment, cardiac injury, and drug delivery methods. Recent work includes developing gene therapies and antibody-drug conjugates targeting cancer cells (including breast cancer and neuroendocrine tumors), as well as studying how mitochondrial dysfunction contributes to heart cell injury and arrhythmias. The lab also works on extracellular vesicles (small cell-derived particles) as tools for delivering treatments to tumors like glioblastoma.
Publication output has been variable but shows a recent sharp increase, particularly in 2024 and projected 2026 counts, following a period of moderate and fluctuating annual output.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Reproducible Computational Analysis for Advanced Dual Payload Antibody-Drug Conjugates
Code Ocean · 2026
- Humanized antibody-drug conjugates for SSTR2-positive tumor treatment
Code Ocean · 2026
- <b>Supplemental </b><b>Figure </b><b>S1</b>
Figshare · 2026
- <b>Supplemental </b><b>Figure </b><b>S1</b>
Figshare · 2026
- Abstract Thu089: Pannexin-2 Deficiency Exacerbates Thapsigargin-induced Cell Injury in Cardiomyocytes
Circulation Research · 2025
- Correction: Si et al. Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment. Pharmaceutics 2020, 12, 1079
Pharmaceutics · 2025
- Combine mitochondrial-targeted gene therapy and chemotherapy to treat triple-negative breast cancer
Figshare · 2025
- mLumiOpto Is a Mitochondrial-Targeted Gene Therapy for Treating Cancer
Cancer Research · 2024
- An Innovative Mitochondrial-targeted Gene Therapy for Cancer Treatment
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Abstract Tu142: Pannexin-2 Deficiency Exacerbates Stress-induced Cell Injury in Cardiomyocytes
Circulation Research · 2024
- Supplementary Data from mLumiOpto Is a Mitochondrial-Targeted Gene Therapy for Treating Cancer
2024
- Data from mLumiOpto Is a Mitochondrial-Targeted Gene Therapy for Treating Cancer
2024
- Characterization of the far-red fluorescent probe MitoView 633 for dynamic mitochondrial membrane potential measurement
Frontiers in Physiology · 2023
- Novel Roles for the Transcriptional Repressor E4BP4 in Both Cardiac Physiology and Pathophysiology
JACC Basic to Translational Science · 2023
- Correction: Chen et al. Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma. Biomedicines 2022, 10, 130
Biomedicines · 2023
- Cancer Research×6
- Circulation Research×5
- Figshare×4
- Pharmaceutics×3
- Methods in molecular biology×3
- Jiashuai Zhang
Medicine · The Ohio State University
- Margaret Liu
Medicine · The Ohio State University
- Daniel C. Koboldt
Medicine · The Ohio State University
- Anthony Lee
Medicine · The Ohio State University
- Anika T. Chowdhury
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile